The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study
Launched by KAROLINSKA INSTITUTET · Dec 5, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
INTRODUCTION Hypertension is common with a prevalence of approximately one third of the adult Swedish population and similar figures reported world wide. It is associated to cardiac structural- and functional changes as well as vascular dysfunction which all can be delayed or reversed by appropriate antihypertensive treatment. Although blood pressure (BP) control is improving, target BP is still reached by less than half of the treated patients. Hypertension is the single risk factor with the greatest attributable risk for incident heart failure (HF) and is considerably more common in HF wi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary hypertension
- • Age ≥ 18 years
- • Preserved cognitive function and expected longevity 1 year
- • Written informed consent
- Exclusion Criteria:
- • Heart failure and/or reduced LVEF
- • Valvular heart disease of hemodynamic importance
- • Resistant hypertension
- • Pregnancy
- • Renal failure, GFR \<30 mL/min/1,73 m2
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Mattias Ekström, Dr
Principal Investigator
Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials